Mga Batayang Estadistika
| CIK | 1062128 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Artemis Therapeutics Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) MANUKA, INC. |
|
| November 14, 2023 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: . . . . . 3235-0058 Washington, D.C. 20549 Expires: April 30, 2025 Estimated average burden hours FORM 12b-25 per response. . . . . . . . 2.50 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-24431 CUSIP NUMBER 04302Q109 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Per |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) MANUKA, INC. |
|
| August 15, 2023 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: . . . . . 3235-0058 Washington, D.C. 20549 Expires: April 30, 2025 Estimated average burden hours FORM 12b-25 per response. . . . . . . . 2.50 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-24431 CUSIP NUMBER 04302Q109 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Per |
|
| May 23, 2023 |
As filed with the Securities and Exchange Commission on May 22, 2023 As filed with the Securities and Exchange Commission on May 22, 2023 Registration No. |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 22, 2023 Manuka, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-24431 84-1417774 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| May 22, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF ARTEMIS THERAPEUTICS, INC. The undersigned, for the purposes of amending the Certificate of Incorporation of Artemis Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The nam |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) ARTEMIS THERAPEUTICS, INC. |
|
| May 15, 2023 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: . . . . . 3235-0058 Washington, D.C. 20549 Expires: April 30, 2025 Estimated average burden hours FORM 12b-25 per response. . . . . . . . 2.50 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-24431 CUSIP NUMBER 04302Q109 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Per |
|
| May 12, 2023 |
As filed with the Securities and Exchange Commission on May 12, 2023 As filed with the Securities and Exchange Commission on May 12, 2023 Registration No. |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 2) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 0-24431 ARTEMIS TH |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 0-24431 ARTEMIS TH |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 0-24431 ARTEMIS THERAPEUTICS, INC. (Ex |
|
| March 31, 2023 |
EXHIBIT 4.2 DESCRIPTION OF SECURITIES General After the Closing of the Share Exchange, the Company’s authorized capital stock consists of 150,000,000 shares of capital stock, par value $0.01 per share, of which 200,000 shares are “blank check” preferred stock, par value $0.01 per share, of which 1,000 are designated as Series A Convertible Preferred Stock (of which 453 have been issued and convert |
|
| January 4, 2023 |
As filed with the Securities and Exchange Commission on January 4, 2023. As filed with the Securities and Exchange Commission on January 4, 2023. Registration No. 333-267534 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Artemis Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation or Org |
|
| December 30, 2022 |
Artemis Therapeutics, Inc. 3 Eliezer Vardinon St., Petach Tikva, Israel 4959507 Artemis Therapeutics, Inc. 3 Eliezer Vardinon St., Petach Tikva, Israel 4959507 December 30, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Artemis Therapeutics, Inc. (CIK 0001062128) Registration Statement No. 333-267534 on Form S-1 (the “Registration Statement”) Ladies and Gentlemen: Artemis Therapeutics, Inc. (the “R |
|
| December 20, 2022 |
As filed with the Securities and Exchange Commission on December 20, 2022. As filed with the Securities and Exchange Commission on December 20, 2022. Registration No. 333-267534 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Artemis Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation or O |
|
| December 20, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) ARTEMIS THERAPEUTICS, INC. |
|
| December 20, 2022 |
Artemis Therapeutics, Inc. 3 Eliezer Vardinon St., Petach Tikva, Israel 4959507 CORRESP 1 filename1.htm Artemis Therapeutics, Inc. 3 Eliezer Vardinon St., Petach Tikva, Israel 4959507 December 20, 2022 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, NE Washington, DC 20549 Re: Artemis Therapeutics, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed November 21, 2022 File No |
|
| November 21, 2022 |
Artemis Therapeutics, Inc. 3 Eliezer Vardinon St., Petach Tikva, Israel 4959507 Artemis Therapeutics, Inc. 3 Eliezer Vardinon St., Petach Tikva, Israel 4959507 November 21, 2022 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, NE Washington, DC 20549 Re: Artemis Therapeutics, Inc. Registration Statement on Form S-1 Filed September 21, 2022 File No. 333- 267534 Ladies and Gentlemen: The pu |
|
| November 21, 2022 |
As filed with the Securities and Exchange Commission on November 21, 2022. As filed with the Securities and Exchange Commission on November 21, 2022. Registration No. 333-267534 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Artemis Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation or O |
|
| November 21, 2022 |
Personal Employment Agreement between Manuka Ltd. and Shimon Citron, dated April 13, 2022. Exhibit 10.9 This is a translation into English of the official Hebrew version of the Personal Employment Agreement between Manuka Ltd. and Shimon Citron. In the event of a conflict between the English and Hebrew texts, the Hebrew text shall prevail. CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM T |
|
| November 21, 2022 |
Form of Indemnification Agreement Exhibit 10.8 FORM OF INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of the day of , 2022, by and Artemis Therapeutics, Inc., a Delaware corporation (the ?Corporation?), and (?Indemnitee?), a director and/or officer of the Corporation. WHEREAS, it is essential to the Corporation to retain and attract as directors and officers the most capable persons available; WH |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) ARTEMIS THERAPEUTICS, INC. |
|
| September 21, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-1 (Form Type) ARTEMIS THERAPEUTICS, INC. |
|
| September 21, 2022 |
Form of Indemnification Agreement Exhibit 10.8 FORM OF INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of the day of , 2022, by and Artemis Therapeutics, Inc., a Delaware corporation (the ?Corporation?), and (?Indemnitee?), a director and/or officer of the Corporation. WHEREAS, it is essential to the Corporation to retain and attract as directors and officers the most capable persons available; WH |
|
| September 21, 2022 |
As filed with the Securities and Exchange Commission on September 21, 2022. As filed with the Securities and Exchange Commission on September 21, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ? Artemis Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? Delaware (State or Other Jurisdiction of Incorporation or Organization)? ? 2844 |
|
| September 9, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF ARTEMIS THERAPEUTICS, INC. The undersigned, for the purposes of amending the Certificate of Incorporation of Artemis Therapeutics, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify that: FIRST: The nam |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 8, 2022 Artemis Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-24431 84-1417774 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) ARTEMIS THERAPEUTICS, INC. |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period |
|
| August 10, 2022 |
DEF 14C 1 zk2228313.htm DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement ARTEMIS THERAPEU |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 27, 2022 Artemis Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-24431 84-1417774 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 2, 2022 |
Exhibit 10.1 SERVICES AGREEMENT This Agreement is made as of July 26, 2022 (the "Effective Date"), by and between Artemis Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, having an office at 8 East 16th Street, Suite 307, New York, NY 10003 ("Artemis") and MANUKA LTD, a limited liability company organized under the laws of the State of Israel, having an office a |
|
| July 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement ARTEMIS THERAPEUTICS, INC. (Name of registrant a |
|
| July 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 20, 2022 Artemis Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-24431 84-1417774 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| July 5, 2022 |
Exhibit 4.1 ARTEMIS THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES D CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Chanan Morris, does hereby certify that: 1. He is the Chief Financial Officer of Artemis Therapeutics, Inc., a Delaware corporation (the ?Corporation?). 2. The Corporation is |
|
| July 5, 2022 |
Exhibit 99.2 MANUKA LTD. FINANCIAL STATEMENTS March 31, 2022 MANUKA LTD. FINANCIAL STATEMENTS AS OF March 31, 2022 U.S. DOLLARS INDEX Page Balance Sheets 1 Statements of Operations 2 Statements of Changes in Shareholders' Equity 3 Statements of Cash Flows 4 Notes to Financial Statements 5-8 MANUKA LTD. INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS U.S. DOLLARS March 31 December 31 Note 2 0 2 2 2 0 |
|
| July 5, 2022 |
Exhibit 10.3 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO MANUKA LTD. IF PUBLICLY DISCLOSED. OMISSIONS ARE DENOTED IN BRACKETS WITH ASTERISKS THROUGHOUT THIS EXHIBIT. AGREEMENT This Agreement (the ?Agreement?) is made as of July 20, 2021 (the ?Effective Date?) by and between Waitemata Manuka H |
|
| July 5, 2022 |
Exhibit 10.7 DEBT FORGIVENESS AGREEMENT THIS DEBT FORGIVENESS AGREEMENT (this ?Agreement?) is made and entered into and effective as of this th day of , 2022 by and between Artemis Therapeutics, Inc., a Delaware corporation (?Artemis?), and (the ?Lender?). WHEREAS, on the terms and subject to the conditions set forth in this Agreement, and as a condition to that certain Share Exchange Agreement by |
|
| July 5, 2022 |
Exhibit 99.3 SELECTED UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION OF ARTEMIS THERAPEUTICS, INC. AND MANUKA LTD., AS OF MARCH 31, 2022 Basis of Pro Forma Presentation The following unaudited pro forma condensed combined financial information (hereinafter the ?Combined Financial Information?) presents the combination of the balance sheet of Artemis Therapeutics, Inc. (?Artemis?) and Manuka Lt |
|
| July 5, 2022 |
Exhibit 10.2 FIRST AMENDMENT TO SHARE EXCHANGE AGREEMENT This First Amendment to the Share Exchange Agreement, dated as of June 30, 2022 (this ?Amendment?), is by and among Artemis Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, having an office for the transaction of business at 8 East 16th Street, Suite 307, New York, NY 10003 (?Purchaser?), MANUKA Ltd., a li |
|
| July 5, 2022 |
List of Subsidiaries (previously filed as Exhibit 21.1 to Current Report 8-K on July 5, 2022). Exhibit 21.1 LIST OF SUBSIDIARIES Entity Name Jurisdiction of Incorporation Manuka Ltd. Israel |
|
| July 5, 2022 |
Exhibit 99.1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Shareholders of Manuka LTD. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheet of Manuka LTD (the "Company") as of December 31, 2021, and 2020, and the related consolidated statements of comprehensive income, shareholders' equity, and cash flows, for the y |
|
| July 5, 2022 |
Exhibit 10.6 ARTEMIS THERAPEUTICS, INC. , 2022 Re: Warrant Exchange Agreement Dear : Reference is made to that certain Warrant issued by Artemis Therapeutics, Inc., a Delaware corporation (the ?Company?), to (the ?Holder?), dated as of October 23, 2017 (the ?Warrants?), attached hereto as Exhibit A, pursuant to which the Company granted the Holder a right to acquire up to an aggregate of shares of |
|
| July 5, 2022 |
Exhibit 10.5 This is a translation into English of the official Hebrew version of the an Import License issued by the Israel Ministry of Health to Manuka Ltd. In the event of a conflict between the English and Hebrew texts, the Hebrew text shall prevail. The cargo will not be released from the port without the authorization of the quarantine station State of Israel Ministry of Health Do not use th |
|
| July 5, 2022 |
Exhibit 10.4 This is a translation into English of the official Hebrew version of the agreement between Manuka Ltd. and Chic Cosmetics Industries 1989 Ltd. In the event of a conflict between the English and Hebrew texts, the Hebrew text shall prevail. CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM |
|
| July 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 30, 2022 Artemis Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-24431 84-1417774 (Commission Fi |
|
| May 23, 2022 |
Exhibit 10.1 SHARE EXCHANGE AGREEMENT This Share Exchange Agreement (the ?Agreement?) dated February, 17, 2022 (the ?Effective Date?), is between and among Artemis Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, having an office for the transaction of business at 8 East 16th Street, Suite 307, New York, NY 10003 (?Purchaser?), MANUKA Ltd., a limited liability c |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) ARTEMIS THERAPEUTICS, INC. |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Perio |
|
| March 9, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 6, 2022 Artemis Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-24431 84-1417774 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 0-24431 ARTEMIS THERAPEUTICS, INC. (Ex |
|
| March 3, 2022 |
Exhibit 4.2 DESCRIPTION OF SECURITIES Under the Amended Certificate of Incorporation (the ?Articles?) of Artemis Therapeutics, Inc. (the ?Company?), the Company is authorized to issue up to fifty-one million (51,000,000) shares of common stock, par value $0.01 per share (the ?Common Stock?) and two-hundred thousand (200,000) shares of preferred stock, par value $0.01 per share (the ?Preferred Stoc |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? ??QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? ??TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) ARTEMIS THERAPEUTICS, INC. |
|
| November 10, 2021 |
Unsecured Promissory Note issued to Harmony (H.A.) Investments Ltd. Exhibit 10.2 ARTEMIS THERAPEUTICS INC. UNSECURED PROMISSORY NOTE Principal Amount: USD $30,000 Original Issuance Date: September 19, 2021 FOR VALUE RECEIVED Artemis Therapeutics Inc., a Delaware corporation (the "Company"), promises to pay to Harmony (H.A.) Investments Ltd. ("Holder"), the principal amount of thirty thousand dollars (USD $30,000) together with all accrued but unpaid interest, or s |
|
| November 10, 2021 |
Unsecured Promissory Note issued to KRNY Ltd. Exhibit 10.1 ARTEMIS THERAPEUTICS INC. UNSECURED PROMISSORY NOTE Principal Amount: USD $30,000 Original Issuance Date: August 15, 2021 FOR VALUE RECEIVED Artemis Therapeutics Inc., a Delaware corporation (the "Company"), promises to pay to KNRY Ltd. ("Holder"), the principal amount of thirty thousand dollars (USD $30,000) together with all accrued but unpaid interest, or such lesser amount as shal |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 4, 2021 Artemis Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-24431 84-1417774 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? ??QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? ??TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) ARTEMIS THERAPEUTICS, INC. |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 000-24431 CUSIP NUMBER (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2021 ? T |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) ARTEMIS THERAPEUTICS, INC. |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 0-24431 ARTEMIS THERAPEUTICS, INC. (Ex |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) ARTEMIS THERAPEUTICS, INC. |
|
| August 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) ARTEMIS THERAPEUTICS, INC. |
|
| May 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) ARTEMIS THERAPEUTICS, INC. |
|
| March 30, 2020 |
ATMS / Artemis Therapeutics, Inc. 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 0-24431 ARTEMIS THERAPEUTICS, INC. (Ex |
|
| November 14, 2019 |
INKS / Inksure Technologies, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) ARTEMIS THERAPEUTICS, INC. |
|
| August 19, 2019 |
INKS / Inksure Technologies, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) ARTEMIS THERAPEUTICS, INC. |
|
| August 19, 2019 |
Exhibit 10.1 ARTEMIS THERAPEUTICS INC. UNSECURED PROMISSORY NOTE Principal Amount: USD $ Original Issuance Date: May 15, 2019 FOR VALUE RECEIVED Artemis Therapeutics Inc., a Delaware corporation (the "Company"), promises to pay to ("Holder"), the principal amount of dollars (USD $) together with all accrued but unpaid interest, or such lesser amount as shall equal the then outstanding principal am |
|
| August 15, 2019 |
INKS / Inksure Technologies, Inc. NT 10-Q - - NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING 000-24431 Commission File Number (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Fo |
|
| May 21, 2019 |
8-K 1 zk1923124.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 21, 2019 (May 15, 2019) Artemis Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-24431 84-1417774 (State or Other Jurisdi |
|
| May 15, 2019 |
INKS / Inksure Technologies, Inc. 10-Q Quarterly Report 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) ARTEMIS THERAPEUTICS, INC. |
|
| April 15, 2019 |
INKS / Inksure Technologies, Inc. 10-K (Annual Report) 10-K 1 zk1922876.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 0-24431 ARTE |
|
| April 1, 2019 |
INKS / Inksure Technologies, Inc. NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING 000-24431 Commission File Number (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2018 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on |
|
| January 16, 2019 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 16, 2019 (January 10, 2019) ARTEMIS THERAPEUTICS, INC. |
|
| January 3, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 2, 2019 (December 31, 2018) ARTEMIS THERAPEUTICS, INC. |
|
| November 13, 2018 |
INKS / Inksure Technologies, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) ARTEMIS THERAPEUTICS, INC. |
|
| August 14, 2018 |
INKS / Inksure Technologies, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) ARTEMIS THERAPEUTICS, INC. |
|
| May 14, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) ARTEMIS THERAPEUTICS, INC. |
|
| April 27, 2018 |
INKS / Inksure Technologies, Inc. 10-K/A (Annual Report) 10-K/A 1 zk1821528.htm 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSIO |
|
| April 2, 2018 |
INKS / Inksure Technologies, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 0-24431 ARTEMIS THERAPEUTICS, INC. |
|
| January 5, 2018 |
8-K 1 zk1820951.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 5, 2018 (January 3, 2018) ARTEMIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Inco |
|
| January 5, 2018 |
EX-10.1 2 exhibit10-1.htm EXHIBIT 10.1 Exhibit 10.1 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment (the “Amendment”), dated as of January 3, 2018, of Employment Agreement (the “Employment Agreement”), dated as of August 1, 2017, between Brian M. Culley, an individual having an address at 2153 Whisper Wind Ln., Encinitas, CA 92024 (the “Executive”) and Artemis Therapeutics Inc., a Del |
|
| November 13, 2017 |
INKS / Inksure Technologies, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) ARTEMIS THERAPEUTICS, INC. |
|
| October 25, 2017 |
EX-3.1 2 exhibit3-1.htm EXHIBIT 3.1 Exhibit 3.1 ARTEMIS THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Brian Culley and Chanan Morris, do hereby certify that: 1. They are the Chief Executive Officer and Chief Financial Officer, respectively, |
|
| October 25, 2017 |
EX-4.1 3 exhibit4-1.htm EXHIBIT 4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXC |
|
| October 25, 2017 |
8-K 1 zk1720648.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 25, 2017 (October 23, 2017) ARTEMIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of In |
|
| October 25, 2017 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ? Agreement?) is dated as of October 23, 2017, between Artemis Therapeutics, Inc., a Delaware corporation (the ? Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ? Purchaser? and collectively, the ? Purchasers?). WHEREAS, subject to the terms and |
|
| August 15, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING 000-24431 Commission File Number (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2017 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Fo |
|
| August 15, 2017 |
INKS / Inksure Technologies, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) ARTEMIS THERAPEUTICS, INC. |
|
| August 10, 2017 |
8-K 1 zk1720407.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 10, 2017 (August 7, 2017) ARTEMIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incor |
|
| August 10, 2017 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement, dated as of August 1, 2017, is made and entered into between Brian M. Culley, an individual having an address at 2153 Whisper Wind Ln., Encinitas, CA 92024 (the “ Executive”) and Artemis Therapeutics Inc., a Delaware corporation (the “ Company”). W I T N E S S E T H: WHEREAS, the Company desires to employ the Executive; and WHEREAS, the |
|
| June 29, 2017 |
exhibit10-1.htm Exhibit 10.1 **Confidential portions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission (the ?Commission?)** LICENSE AGREEMENT This License Agreement (this ? Agreement?) is entered into on May 31, 2016, by and between Hadasit Medical Research Services & Development, Ltd. of Jerusalem Bio Park |
|
| June 29, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A (Amendment No. |
|
| May 16, 2017 |
Exhibit 99.1 Corporate PresentationMay 2017 Forward Looking Statements This presentation contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of our management only. The following factors, among others, c |
|
| May 16, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 16, 2017 (May 16, 2017) Artemis Therapeutics, Inc. |
|
| May 15, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) ARTEMIS THERAPEUTICS, INC. |
|
| May 11, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 Commission file number: 001-24431 ARTEMIS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 84-1417774 (State or other jurisdiction of i |
|
| March 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 0-24431 ARTEMIS THERAPEUTICS, INC. |
|
| March 30, 2017 |
EX-4.2 4 exhibit4-2.htm EXHIBIT 4.2 Exhibit 4.2 STOCK OPTION AGREEMENT THIS STOCK OPTION AGREEMENT (the “Agreement”) is made and entered into as of March, 2017, by and between Artemis Therapeutics, Inc., a Delaware corporation (the “Corporation” or “Company”) and Hadasit Medical Research Services & Development Ltd. (the “Optionee”). This Agreement is being issued in place of that certain option ag |
|
| March 30, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A (Amendment No. |
|
| March 30, 2017 |
Exhibit 4.1 STOCK OPTION AGREEMENT THIS STOCK OPTION AGREEMENT (the ?Agreement?) is made and entered into as of March, 2017, by and between Artemis Therapeutics, Inc., a Delaware corporation (the ?Corporation? or ?Company?) and Dr. Dana Wolf (the ?Optionee?). This Agreement is being issued in place of that certain option agreement between Artemis Pharma Inc. (formerly known as Artemis Therapeutics |
|
| January 17, 2017 |
EX-10.1 2 exhibit10-1.htm EXHIBIT 10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement, dated as of January 5, 2017, is made and entered into between Peter N. Payne, an individual having an address at 3605 Laurel Hills Road, Raleigh, North Carolina 27612 (the “Executive”) and New York Global Innovations Inc., a Delaware corporation (the “Company”). W I T N E S S E T H: WHEREAS, the Com |
|
| January 17, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 17, 2017 (January 10, 2017) Artemis Therapeutics, Inc. |
|
| December 20, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 20, 2016 (December 16, 2016) Artemis Therapeutics, Inc. |
|
| December 20, 2016 |
CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF NEW YORK GLOBAL INNOVATIONS INC. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF NEW YORK GLOBAL INNOVATIONS INC. The undersigned, for the purposes of amending the Certificate of Incorporation of New York Global Innovations Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify that: FI |
|
| December 15, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A (Amendment No. |
|
| December 15, 2016 |
exhibit10-1.htm Exhibit 10.1 **Confidential portions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission (the ?Commission?)** LICENSE AGREEMENT This License Agreement (this ? Agreement?) is entered into on May 31, 2016, by and between Hadasit Medical Research Services & Development, Ltd. of Jerusalem Bio Park |
|
| November 22, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement NEW YORK GLOBAL INNOVATIONS INC. (Name of regist |
|
| November 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) NEW YORK GLOBAL INNOVATIONS INC. |
|
| November 10, 2016 |
Inksure Technologies SC PRE 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement NEW YORK GLOBAL INNOVATIONS INC. (Name of regist |
|
| October 18, 2016 |
EX-10.3 6 exhibit10-3.htm EXHIBIT 10.3 Exhibit 10.3 CONSULTING AGREEMENT This CONSULTING AGREEMENT (this “Agreement”) is entered into as of the Effective Date (as defined below), by and between: Hadasit Medical Research Services and Development Ltd. (“Hadasit”), whose address, for the purposes hereof, is P.O. Box 12000, Jerusalem 9112001; Professor Dana Wolf ( “Prof. Wolf”), whose address, for the |
|
| October 18, 2016 |
EX-10.2 5 exhibit10-2.htm EXHIBIT 10.2 Exhibit 10.2 FIRST AMENDMENT TO THE LICENSE AGREEMENT This First Amendment to the License Agreement (this "Amendment") is entered into on July 27, 2016 by and between Hadasit Medical Research Services & Development Ltd., of Jerusalem Bio Park, Hadassah Ein-Kerem Medical Center, P.O.B. 12000, Jerusalem 91120, Hong Kong University of Science and Technology R an |
|
| October 18, 2016 |
8-K/A 1 zk1619085.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 18, 2016 (August 23, 2016) NEW YORK GLOBAL INNOVATIONS INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (Stat |
|
| October 18, 2016 |
ARTEMIS THERAPEUTICS INC. NON-QUALIFIED STOCK OPTION AGREEMENT EX-4.1 2 exhibit4-1.htm EXHIBIT 4.1 Exhibit 4.1 ARTEMIS THERAPEUTICS INC. NON-QUALIFIED STOCK OPTION AGREEMENT Artemis Therapeutics Inc., a Delaware corporation (the "Company"), hereby grants the following stock option (the "Option") pursuant to its 2016 Stock Option and Incentive Plan. The terms and conditions attached hereto are also a part hereof. Name of optionee (the "Optionee"): Dana Wolf Da |
|
| October 18, 2016 |
EX-10.1 4 exhibit10-1.htm EXHIBIT 10.1 Exhibit 10.1 **Confidential portions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission (the “Commission”)** LICENSE AGREEMENT This License Agreement (this “Agreement”) is entered into on May 31, 2016, by and between Hadasit Medical Research Services & Development, Ltd. |
|
| October 18, 2016 |
ARTEMIS THERAPEUTICS INC. Non-Qualified Stock Option Agreement EX-4.2 3 exhibit4-2.htm EXHIBIT 4.2 Exhibit 4.2 ARTEMIS THERAPEUTICS INC. Non-Qualified Stock Option Agreement Artemis Therapeutics Inc., a Delaware corporation (the “Company”), hereby grants the following stock option (the “Option”) pursuant to its 2016 Stock Option and Incentive Plan. The terms and conditions attached hereto are also a part hereof. Name of optionee (the “Optionee”): Hadasit Medi |
|
| August 29, 2016 |
EX-4.1 2 exhibit4-1.htm EXHIBIT 4.1 Exhibit 4.1 NEW YORK GLOBAL INNOVATIONS INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Gadi Peleg and Chanan Morris, do hereby certify that: 1. They are the Chairman and Chief Financial Officer, respectively, of New Yor |
|
| August 29, 2016 |
NEW YORK GLOBAL INNOVATIONS INC. PRO FORMA COMBINED FINANCIAL STATEMENTS INTRODUCTORY NOTE EX-99.1 5 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 NEW YORK GLOBAL INNOVATIONS INC. PRO FORMA COMBINED FINANCIAL STATEMENTS INTRODUCTORY NOTE On August 2, 2016, New York Global Innovations, Inc. entered into an Agreement and Plan of Merger with Artemis Therapeutics Inc., a Delaware corporation (“Artemis”) and Artemis Acquisition Corp., a Delaware corporation and a wholly-owned subsidiary of the C |
|
| August 29, 2016 |
exhibit10-2.htm Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ? Agreement?) is dated as of August 2, 2016, between New York Global Innovations Inc., a Delaware corporation (the ? Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ? Purchaser? and collectively, the ? Purchasers?). WHEREAS, subje |
|
| August 29, 2016 |
exhibit10-2.htm Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ? Agreement?) is dated as of August 2, 2016, between New York Global Innovations Inc., a Delaware corporation (the ? Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ? Purchaser? and collectively, the ? Purchasers?). WHEREAS, subje |
|
| August 29, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 29, 2016 (August 23, 2016) NEW YORK GLOBAL INNOVATIONS INC. |
|
| August 29, 2016 |
Exhibit 4.2 NEW YORK GLOBAL INNOVATIONS INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Gadi Peleg and Chanan Morris, do hereby certify that: 1. They are the Chairman and Chief Financial Officer, respectively, of New York Global Innovations Inc., a Delawar |
|
| August 29, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 29, 2016 (August 23, 2016) NEW YORK GLOBAL INNOVATIONS INC. |
|
| August 3, 2016 |
EX-10.2 6 exhibit10-2.htm EXHIBIT 10.2 Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 2, 2016, between New York Global Innovations Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchaser |
|
| August 3, 2016 |
EX-4.2 3 exhibit4-2.htm EXHIBIT 4.2 EXHIBIT 4.2 NEW YORK GLOBAL INNOVATIONS INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Gadi Peleg and Chanan Morris, do hereby certify that: 1. They are the Chairman and Chief Financial Officer, respectively, of New Yor |
|
| August 3, 2016 |
SECOND AMENDMENT TO SERIES A WARRANT exhibit4-3.htm Exhibit 4.3 SECOND AMENDMENT TO SERIES A WARRANT SECOND AMENDMENT dated August 2, 2016 to Series A Warrant ("Series A Warrant") dated April 8, 2008, as amended on January 19, 2010 (the “First Amendment”), issued by New York Global Innovations Inc. (formerly known as Inksure Technologies, Inc.) ("Issuer") to Smithfield Fiduciary LLC ("Holder") for 2,153,433 shares of Common Stock of |
|
| August 3, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 zk1618798.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 3, 2016 (August 2, 2016) NEW YORK GLOBAL INNOVATIONS INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of |
|
| August 3, 2016 |
EX-10.1 5 exhibit10-1.htm EXHIBIT 10.1 Exhibit 10.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG NEW YORK GLOBAL INNOVATIONS INC., ARTEMIS ACQUISITION CORP. AND ARTEMIS THERAPEUTICS INC. AUGUST 2, 2016 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 Definitions 1 ARTICLE II THE MERGER 5 Section 2.1 Merger 5 Section 2.2 Effective Time 5 Section 2.3 Certificate of Incorporation; By-laws; Director |
|
| August 3, 2016 |
EX-4.1 2 exhibit4-1.htm EXHIBIT 4.1 Exhibit 4.1 NEW YORK GLOBAL INNOVATIONS INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Gadi Peleg and Chanan Morris, do hereby certify that: 1. They are the Chairman and Chief Financial Officer, respectively, of New Yor |
|
| July 21, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) NEW YORK GLOBAL INNOVATIONS INC. |
|
| May 3, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) NEW YORK GLOBAL INNOVATIONS INC. |
|
| March 10, 2016 |
Exhibit 10.5 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this ?Agreement?) is made as of July 1, 2014 by and between New York Global Innovations, Inc., and its wholly owned subsidiaries (collectively the ?Company?) and Gilat Technologies (in formation), a company organized under the laws of the State of Israel with offices located at 8 Rachel Street, Givatayim, (the ?Consultant?). W I T N E S |
|
| March 10, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 0-24431 NEW YORK GLOBAL INNOVATIONS |
|
| November 4, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) NEW YORK GLOBAL INNOVATIONS INC. |
|
| October 8, 2015 |
Inksure Technologies 8-K (Current Report/Significant Event) zk1517397.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 8, 2015 (October 7, 2015) NEW YORK GLOBAL INNOVATIONS INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorpor |
|
| August 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) NEW YORK GLOBAL INNOVATIONS INC. |
|
| May 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) NEW YORK GLOBAL INNOVATIONS INC. |
|
| April 15, 2015 |
CERTIFICATION OF CHIEF FINANCIAL OFFICER EXHIBIT 31.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER I, Chanan Morris, certify that: 1. I have reviewed this annual report on Form 10-K for the year ended December 31, 2014 of New York Global Innovations Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circum |
|
| April 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 0-24431 NEW YORK GLOBAL INNOVATIONS |
|
| March 31, 2015 |
zk1516539.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING 1-16817 Commission File Number (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2014 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transit |
|
| February 26, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 26, 2015 (February 24, 2015) NEW YORK GLOBAL INNOVATIONS INC. |
|
| December 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 15, 2014 (December 9, 2014) NEW YORK GLOBAL INNOVATIONS INC. |
|
| November 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) NEW YORK GLOBAL INNOVATIONS INC. |
|
| October 2, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 2, 2014 (September 10, 2014) NEW YORK GLOBAL INNOVATIONS INC. |
|
| August 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) NEW YORK GLOBAL INNOVATIONS INC. |
|
| August 14, 2014 |
EX-10.1 2 exhibit10-1.htm EXHIBIT 10.1 Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this “agreement”) is made as of July 1, 2014 by and between New York Global Innovations, Inc., and its wholly owned subsidiaries (collectively the ACompany@) and Gilat Technologies (in formation), a company organized under the laws of the State of Israel with offices located at 8 Rachel Street, Giva |
|
| July 8, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 8, 2014 (July 1, 2014) NEW YORK GLOBAL INNOVATIONS INC. |
|
| May 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) NEW YORK GLOBAL INNOVATIONS INC. |
|
| April 14, 2014 |
CERTIFICATE OF INCORPORATION INKSURE TECHNOLOGIES (DELAWARE) INC. EXHIBIT 3.1 CERTIFICATE OF INCORPORATION OF INKSURE TECHNOLOGIES (DELAWARE) INC. The undersigned, a natural person, for the purpose of organizing a corporation for conducting the business and promoting the purposes hereinafter stated, under the provisions and subject to the requirements of the laws of the State of Delaware (particularly Chapter 1, Title S of the Delaware Code and the acts amendato |
|
| April 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 0-24431 NEW YORK GLOBAL INNOVATIONS |
|
| March 27, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 000-24431 (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2013 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report o |
|
| March 6, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 28, 2014 NEW YORK GLOBAL INNOVATIONS INC. |
|
| March 6, 2014 |
AMENDMENT NO. 2 TO ASSET PURCHASE AGREEMENT Exhibit 2.1 AMENDMENT NO. 2 TO ASSET PURCHASE AGREEMENT Reference is made to that certain Asset Purchase Agreement (the “Agreement”) dated and entered into on October 1, 2013 by and among (1) InkSure Technologies Inc., a Delaware corporation (“InkSure Parent”); (2) InkSure Inc., a Delaware corporation (“InkSure Delaware Sub”); (3) InkSure Ltd., an Israeli corporation (“InkSure Israeli Sub”) (InkSu |
|
| February 14, 2014 |
Submission of Matters to a Vote of Security Holders - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 11, 2014 INKSURE TECHNOLOGIES INC. |
|
| February 11, 2014 |
ATMS / Artemis Therapeutics, Inc. / LINEBERGER JAMES E - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* InkSure Technologies Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45727E (CUSIP Number) James E. Lineberger, Jr. Lineberger & Co., LLC 1120 Boston Post Road Darien, CT 06820 203-655-7578 With a copy to: Rush |
|
| January 14, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 9, 2014 INKSURE TECHNOLOGIES INC. |
|
| January 14, 2014 |
AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT Exhibit 2.1 AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT Reference is made to that certain Asset Purchase Agreement (the “Agreement”) dated and entered into on October 1, 2013 by and among (1) InkSure Technologies Inc., a Delaware corporation (“InkSure Parent”); (2) InkSure Inc., a Delaware corporation (“InkSure Delaware Sub”); (3) InkSure Ltd., an Israeli corporation (“InkSure Israeli Sub”) (InkSu |
|
| January 13, 2014 |
Page 1 of 11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 8)* InkSure Technologies Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45727E (CUSIP Number) James E. Lineberger, Jr. Lineberger & Co., LLC 1120 Boston Post Road Darien, CT 06820 203-655-7578 (Name, |
|
| January 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant x Filed by a party other than the registrant ¨ Check the appropriate box: o Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240. |
|
| January 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant x Filed by a party other than the registrant ¨ Check the appropriate box: o Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material Pursuant to §240. |
|
| December 26, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant x Filed by a party other than the registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240. |
|
| December 24, 2013 |
InkSure Technologies Inc. 18 East 16th Street, Suite 307, New York, NY 10003 December 24, 2013 VIA EDGAR AND EMAIL Mrs. Sherry Haywood, Staff Attorney Mr. Ernst Greene, Staff Accountant Mr. John Cash, Accounting Branch Chief Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: InkSure Technologies Inc. (the "Company") Amendm |
|
| December 17, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 17, 2013 (December 13, 2013) INKSURE TECHNOLOGIES INC. |
|
| November 25, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant x Filed by a party other than the registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240. |
|
| November 25, 2013 |
InkSure Technologies Inc. 18 East 16th Street, Suite 307, New York, NY 10003 November 25, 2013 VIA EDGAR AND EMAIL Mrs. Sherry Haywood, Staff Attorney Mr. Ernst Greene, Staff Accountant Mr. John Cash, Accounting Branch Chief Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: InkSure Technologies Inc. (the "Company") Prelim |
|
| November 12, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) INKSURE TECHNOLOGIES INC. |
|
| November 7, 2013 |
ATMS / Artemis Therapeutics, Inc. / Gilat Tal - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 InkSure Technologies Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45727E (CUSIP Number) Tal Gilat President and Chief Executive Officer InkSure Technologies Inc. 18 East 16th Street, Suite 307 New York, New York 10003 (Name, Address and Te |
|
| November 4, 2013 |
ATMS / Artemis Therapeutics, Inc. / Bettsak Jonathan - SC 13D Activist Investment SC 13D 1 zk1313803.htm SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 InkSure Technologies Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45727E (CUSIP Number) Tal Gilat President and Chief Executive Officer InkSure Technologies Inc. 18 East 16th Street, Suite 307 New York, New Yo |
|
| November 4, 2013 |
ATMS / Artemis Therapeutics, Inc. / Peleg Gadi - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 InkSure Technologies Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45727E (CUSIP Number) Tal Gilat President and Chief Executive Officer InkSure Technologies Inc. 18 East 16th Street, Suite 307 New York, New York 10003 (Name, Address and Te |
|
| October 22, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant x Filed by a party other than the registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240. |
|
| October 21, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 21, 2013 (October 21, 2013) INKSURE TECHNOLOGIES INC. |
|
| October 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 15, 2013 (October 13, 2013) INKSURE TECHNOLOGIES INC. |
|
| October 11, 2013 |
ATMS / Artemis Therapeutics, Inc. / ICTS INTERNATIONAL N V - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3) InkSure Technologies Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45727E (CUSIP Number) ICTS International NV Walaardt Sacr?straat 425-4 1117BM Schiphol Oost The Netherlands (Name, Address and Telephone Number of Person |
|
| October 11, 2013 |
ATMS / Artemis Therapeutics, Inc. / SPECTRA SYSTEMS CORP - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 InkSure Technologies Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45727E (CUSIP Number) Nabil M. Lawandy, PH.D. President and Chief Executive Officer Spectra Systems Corporation 321 South Main Street, Suite 102 Providence, Rhode Island 029 |
|
| October 11, 2013 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Schedule 13D/A with respect to the Common Stock, $.01 par value per share, of InkSure Technologies Inc., dated as of October 11, 2013, is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securitie |
|
| October 11, 2013 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Schedule 13D with respect to the Common Stock, $.01 par value per share, of InkSure Technologies Inc., dated as of October 11, 2013, is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities |
|
| October 3, 2013 |
Exhibit 2.1 ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (the "Agreement") dated and entered into on October 1, 2013 by and among (1) InkSure Technologies Inc., a Delaware corporation (“InkSure Parent”); (2) InkSure Inc., a Delaware corporation (“InkSure Delaware Sub”); (3) InkSure Ltd., an Israeli corporation (“InkSure Israeli Sub”) (InkSure Parent, InkSure Delaware Sub and InkSure Isra |
|
| October 3, 2013 |
EX-2.2 3 exhibit2-2.htm EXHIBIT 2.2 Exhibit 2.2 STOCKHOLDER VOTING AGREEMENT This Stockholder Voting Agreement (this “Agreement”) is made and entered into as of October 1, 2013, by and among InkSure Technologies Inc., a Delaware corporation (“InkSure Parent”), Spectra Systems Corporation, a Delaware corporation (“Buyer”) and the undersigned stockholder (“Stockholder”) of InkSure Parent. RECITALS A |
|
| October 3, 2013 |
8-K 1 zk1313695.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 1, 2013 INKSURE TECHNOLOGIES INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE (State or Other Jurisdiction of Incorporation) 000-2443 |
|
| October 3, 2013 |
InkSure Announces Entry into a Purchase Agreement to Sell Its Assets EX-99 4 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 InkSure Announces Entry into a Purchase Agreement to Sell Its Assets Press Release: InkSure Technologies Inc. – Tues, Oct 2, 2013 6:00 AM EDT NEW YORK, N.Y. – October 2, 2013 – (BUSINESS WIRE) InkSure Technologies Inc. (OTCBB: INKS) is pleased to announce that it has entered into an Asset Purchase Agreement with Spectra Systems Corporation, or Spec |
|
| August 12, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) INKSURE TECHNOLOGIES INC. |
|
| May 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) INKSURE TECHNOLOGIES INC. |
|
| March 29, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 0-24431 INKSURE TECHNOLOGIES INC. ( |
|
| January 31, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported January 26, 2013): January 31, 2013 INKSURE TECHNOLOGIES INC. |
|
| December 21, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 21, 2012 (December 18, 2012) INKSURE TECHNOLOGIES INC. |
|
| December 13, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 13, 2012 (December 3, 2012) INKSURE TECHNOLOGIES INC. |
|
| November 20, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| November 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) INKSURE TECHNOLOGIES INC. |
|
| August 20, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) INKSURE TECHNOLOGIES INC. |
|
| August 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 000-24431 (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2012 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Fo |
|
| July 18, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 18, 2012 (July 8, 2012) INKSURE TECHNOLOGIES INC. |
|
| May 21, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Commission file number 0-24431) INKSURE TECHNOLOGIES INC. |
|
| May 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 000-24431 (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 2012 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on F |
|
| March 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2012 (March 13, 2012) INKSURE TECHNOLOGIES INC. |
|
| March 14, 2012 |
InkSure Technologies Announces 2011 Fiscal Year Financial Results Exhibit 99.1 InkSure Technologies Announces 2011 Fiscal Year Financial Results March 2012, New York InkSure Technologies Inc. (INKS.OB), the global leader in machine-readable taggant technology for anti-counterfeiting and brand protection, today announced financial results for the fiscal year ended December 31, 2011. InkSure's president & CEO Tal Gilat, attributes the growth in revenues to a funda |
|
| March 12, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 0-24431 INKSURE TECHNOLOGIES INC. ( |
|
| November 9, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT (Commission File no. 0-24431) INKSURE TECHNOLOGIES INC. (Exact name of registrant as specified in its |
|
| September 13, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 13, 2011 (September 8, 2011) INKSURE TECHNOLOGIES INC. |
|
| September 12, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) InkSure Technologies Inc. - (Name of Issuer) Common Stock, $0.01 par value per share - (Title of Class of Securities) 45727E - (CUSIP Number) September 6, 2011 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| September 6, 2011 |
Exhibit 10.2 STOCK REPURCHASE AGREEMENT This Stock Repurchase Agreement (this ?Agreement?) dated as of August 31, 2011 by and between Inksure Technologies Inc., a Delaware corporation with its principal business address at 589 Fifth Avenue, Suite 401, New York, New York 10017, USA (the ?Company?) and Dr. Haim Kaplan, an Israeli citizen with an address at 31 Shmuel Tamir St., Tel Aviv, 69637, Israe |
|
| September 6, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 6, 2011 (September 6, 2011) INKSURE TECHNOLOGIES INC. |
|
| September 6, 2011 |
EX-10.1 2 exhibit10-1.htm EXHIBIT 10.1 Exhibit 10.1 STOCK REPURCHASE AGREEMENT This Stock Repurchase Agreement (this “Agreement”) dated as of August 23, 2011 by and between Inksure Technologies, Inc., a Delaware corporation with its principal business address at 589 Fifth Avenue, Suite 401, New York, New York 10017, USA (the “Company”) and Mr. Yaron Meerfeld, an Israeli citizen with an address at |
|
| August 15, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT (Commission File no. 0-24431) INKSURE TECHNOLOGIES INC. (Exact name of registrant as specified in its char |
|
| August 9, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 16, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT (Commission File no. 0-24431) INKSURE TECHNOLOGIES INC. (Exact name of registrant as specified in its cha |
|
| April 21, 2011 |
Page 1 of 11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 7)* InkSure Technologies Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45727E (CUSIP Number) James E. Lineberger, Jr. Lineberger & Co., LLC 1120 Boston Post Road Darien, CT 06820 203-655-7578 (Name, |
|
| March 30, 2011 |
10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 - FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2010 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 0-24431 INKSURE TECHNOLOG |
|
| March 30, 2011 |
EXHIBIT 10.6 AMENDMENT NO.1 TO EMPLOYMENT AGREEMENT (Signed in Tel Aviv on 1st of March, 2011) THIS AMENDMENT NO.1 TO EMPLOYMENT AGREEMENT (this "Amendment") shall become effective as of the 1st day of January 2011 (the "Effective Date"), by and between Inksure Technologies, Inc., a Delaware corporation (the "Company") and Tal Gilat (the "Employee"). WHEREAS, the Company and the Employee have ente |
|
| November 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2010 [] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT (COMMISSION FILE NO. 0-24431) - INKSURE TECHNOLOGIES INC. (EXACT NAME OF REGISTRANT AS SPECIFIED I |
|
| July 30, 2010 |
10-Q ================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 4, 2010 |
10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2010 (COMMISSION FILE NO. 0-24431) - INKSURE TECHNOLOGIES INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE 84-1417774 State or other jurisdiction of (I.R.S. Emp |
|
| April 1, 2010 |
Page 1 of 11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 6)* InkSure Technologies Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45727E (CUSIP Number) James E. Lineberger, Jr. Lineberger & Co., LLC 1120 Boston Post Road Darien, CT 06820 203-655-7578 (Name, |
|
| April 1, 2010 |
Page 1 of 11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 5)* InkSure Technologies Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45727E (CUSIP Number) James E. Lineberger, Jr. Lineberger & Co., LLC 1120 Boston Post Road Darien, CT 06820 203-655-7578 (Name, |
|
| March 16, 2010 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): MARCH 16, 2010 (MARCH 11, 2010) INKSURE TECHNOLOGIES INC. |
|
| March 16, 2010 |
EXHIBIT 10.1 INKSURE TECHNOLOGIES INC. EXHIBIT "B" SUBSCRIPTION DOCUMENTS FOR SHARES MINIMUM SHARES AND AMOUNT SALE OF 17,000,000 SHARES OF COMMON STOCK (THE "SHARES") (WHICH AFTER ISSUANCE WOULD REPRESENT APPROXIMATELY FIFTY-ONE (51%) PERCENT OF THE TOTAL ISSUED AND OUTSTANDING SHARES OF THE COMPANY) AT $0.125 PER SHARE FOR TOTAL CONSIDERATION OF $2,125,000 (THE "MINIMUM SHARES") MAXIMUM SHARES A |
|
| February 26, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 - FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2009 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 0-24431 INKSURE TECHNOLOGIES, |
|
| February 11, 2010 |
Page 1 of 11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 5)* InkSure Technologies Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45727E (CUSIP Number) James E. Lineberger, Jr. Lineberger & Co., LLC 1120 Boston Post Road Darien, CT 06820 203-655-7578 (Name, |
|
| January 21, 2010 |
EX-4.1 2 exhibit4-1.htm EXHIBIT 4.1 FIRST AMENDMENT TO SERIES A WARRANT FIRST AMENDMENT dated JANUARY 19, 2010 to Series A Warrant ("Series A Warrant") dated April 8, 2008 issued by Inksure Technologies, Inc. ("Issuer") to Smithfield Fiduciary LLC ("Holder") for 3,570,337 shares of Common Stock of Issuer. FOR VALUABLE CONSIDERATION, the receipt and sufficiency of which is hereby acknowledged, Issu |
|
| January 21, 2010 |
EXHIBIT 10.1 PURCHASE AGREEMENT AGREEMENT dated as of January 19, 2010 by and among Inksure Technologies, Inc., a Delaware corporation (the "Company"), on the one hand, and Smithfield Fiduciary LLC ("Smithfield") and the Irrevocable Trust of James E. Lineberger U/A dated December 17, 1998, Rockmore Investment Master Fund LTD, Iroquois Master Fund, LTD, and Portside Growth and Opportunity Fund (all |
|
| January 21, 2010 |
EX-10.2 4 exhibit10-2.htm EXHIBIT 10.2 ASSIGNMENT OF SENIOR SECURED CONVERTIBLE NOTE For valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned, Smithfield Fiduciary LLC, hereby assigns to the parties listed on Exhibit A annexed hereto all its rights, title and interest in and to that certain Senior Secured Convertible Note attached hereto in the princ |
|
| January 21, 2010 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): JANUARY 21, 2010 (JANUARY 19, 2010) INKSURE TECHNOLOGIES INC. |
|
| November 13, 2009 |
10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2009 (COMMISSION FILE NO. 0-24431) - INKSURE TECHNOLOGIES INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE 84-1417774 State or other jurisdiction of (I.R.S. |
|
| August 5, 2009 |
10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2009 (COMMISSION FILE NO. 0-24431) - INKSURE TECHNOLOGIES INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE 84-1417774 State or other jurisdiction of (I.R.S. Empl |
|
| March 31, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 - FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2008, OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 0-24431 INKSURE TECHNOLOGIES, |
|
| May 15, 2008 |
EXHIBIT 10.1 EMPLOYMENT AGREEMENT Made and entered into this 13th day of April, 2008 (the "Effective Date"). Between: INKSURE TECHNOLOGIES INC. a Delaware corporation (the "Company"), with offices at 1770 N.W. 64th St., Suite 350, Fort Lauderdale, FL 33309, USA (HEREINAFTER THE "COMPANY"); ON THE FIRST PART And: Mr., Tzlil Peker, a citizen of Israel, ID Number , with an address at , Israel (HEREIN |
|
| May 15, 2008 |
10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2008 (COMMISSION FILE NO. 0-24431) - INKSURE TECHNOLOGIES INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE 84-1417774 State or other jurisdiction of (I.R.S. Emp |
|
| May 7, 2008 |
Page 1 of 11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 4)* InkSure Technologies Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45727E (CUSIP Number) James E. Lineberger, Jr. Lineberger & Co., LLC 1120 Boston Post Road Darien, CT 06820 203-655-7578 (Name, |
|
| May 2, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 1, 2008 INKSURE TECHNOLOGIES, INC. |
|
| May 2, 2008 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE TZLIL PEKER JOINS INKSURE TECHNOLOGIES AS CHIEF FINANCIAL OFFICER FT. LAUDERDALE, Florida, May 1,2008 - InkSure Technologies Inc. (OTC Bulletin Board: INKS - NEWS), a leading provider of covert machine-readable security solutions for the prevention of counterfeiting, fraud and diversion, today announced that Tzlil Peker has joined the Company's executive manageme |
|
| April 23, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) APRIL 23, 2008 INKSURE TECHNOLOGIES, INC. |
|
| April 23, 2008 |
EXHIBIT 99.1 April 22, 2008 Dear Shareholder: We recently closed another round of financing and I wanted to take this opportunity to review the status of the company, our achievements to date, as well as share with you some thoughts and plans for the future. As I look back on our progress, I am sure that I share with you a sense of disappointment. Our sales have not met our expectations. Throughou |
|
| April 10, 2008 |
10KSB 1 zk84906.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended DECEMBER 31, 2007. OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-24431 |
|
| April 9, 2008 |
EXHIBIT 10.2 SECURITY AGREEMENT SECURITY AGREEMENT, dated as of April 8, 2008 (this "AGREEMENT"), made by each of the parties set forth on the signature pages hereto (each a "GRANTOR", and collectively, the "GRANTORS"), in favor of SMITHFIELD FIDUCIARY LLC, a company organized under the laws of the Cayman Islands, in its capacity as collateral agent (in such capacity, the "COLLATERAL AGENT") to th |
|
| April 9, 2008 |
EX-4.2 3 exhibit4-2.htm EXHIBIT 4.2 [FORM OF SENIOR SECURED CONVERTIBLE NOTE] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED ( |
|
| April 9, 2008 |
EXHIBIT 10.1 AMENDMENT, EXCHANGE AND PURCHASE AGREEMENT AMENDMENT, EXCHANGE AND PURCHASE AGREEMENT (this "AGREEMENT"), dated as of April 8, 2008, by and between InkSure Technologies Inc., a Delaware corporation, with headquarters located at 1770 N.W. 64th Street, Fort Lauderdale, Florida 33309 (the "COMPANY"), and [Smithfield Fiduciary LLC][OTHER INVESTORS] (the "INVESTOR"). WHEREAS: A. The Compan |
|
| April 9, 2008 |
EX-10.3 7 exhibit10-3.htm EXHIBIT 10.3 INKSURE TECHNOLOGIES, INC. FORM OF LOCK-UP AGREEMENT April 8, 2008 InkSure Technologies Inc. 1770 N.W. 64th Street Fort Lauderdale, Florida 33309 Re: INKSURE TECHNOLOGIES INC. - LOCK-UP AGREEMENT Dear Sirs: This Lock-Up Agreement is being delivered to you in connection with the Amendment, Exchange and Purchase Agreements (the "AMENDMENT, EXCHANGE AND PURCHASE |
|
| April 9, 2008 |
EX-4.3 4 exhibit4-3.htm EXHIBIT 4.3 [FORM OF SERIES [A] [B-1][B-2] WARRANT] [INSERT IN SERIES A AND SERIES B-2 WARRANTS: NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERE |
|
| April 9, 2008 |
EX-4.1 2 exhibit4-1.htm EXHIBIT 4.1 [FORM OF AMENDED AND RESTATED SENIOR SECURED CONVERTIBLE NOTE] INKSURE TECHNOLOGIES INC. AMENDED AND RESTATED SENIOR SECURED CONVERTIBLE NOTE Issuance Date: September 30, 2005 Original Principal Amount: U.S. $[] FOR VALUE RECEIVED, InkSure Technologies Inc., a Delaware corporation (the "COMPANY"), hereby promises to pay to [SMITHFIELD FIDUCIARY LLC][OTHER BUYERS |
|
| April 9, 2008 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) APRIL 8, 2008 INKSURE TECHNOLOGIES, INC. |
|
| October 3, 2007 |
Page 1 of 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 3)* InkSure Technologies Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45727E (CUSIP Number) James E. Lineberger, Jr. Lineberger & Co., LLC 1120 Boston Post Road Darien, CT 06820 203-655-7578 (Name, |
|
| September 20, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2)* InkSure Technologies Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45727E (CUSIP Number) James E. Lineberger, Jr. Lineberger & Co., LLC 1120 Boston Post Road Darien, CT 06820 203-655-7578 (Name, Address and |
|
| May 21, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X |
|
| May 11, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [X] Preliminary Proxy Statement [] Confidential, for use of the commission only (as permitted by rule 14a-6(e)(2)) [ |
|
| November 14, 2006 |
10-QSB U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB (Mark One) [X] Quarterly report pursuant to Sections 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2006 [] Transition report pursuant to Sections 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-24431 INKSU |
|
| October 3, 2002 |
EX-99.E 8 e835804.txt EXHIBIT E FORM OF CERTIFICATE OF AMENDMENT TO THE ARTICLES OF INCORPORATION OF LIL MARC, INC. The undersigned, President of Lil Marc, Inc. a Nevada corporation (the "Company"), acting pursuant to the provisions of Sections 78.385 and 78.390 of the Nevada Revised Statutes, for the purpose of amending the Articles of Incorporation of said corporation, does hereby certify that t |
